C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $428,236 | +225.6% | 75,794 | +7.2% | 0.08% | +192.9% |
| Q3 2023 | $131,508 | -18.5% | 70,703 | +20.6% | 0.03% | -12.5% |
| Q2 2023 | $161,279 | -3.6% | 58,647 | +10.1% | 0.03% | -33.3% |
| Q1 2023 | $167,293 | +13.7% | 53,278 | +113.7% | 0.05% | -66.4% |
| Q4 2022 | $147,105 | -34.0% | 24,933 | -2.1% | 0.14% | -30.2% |
| Q3 2022 | $223,000 | +21.9% | 25,470 | +4.8% | 0.20% | +47.5% |
| Q2 2022 | $183,000 | -65.5% | 24,314 | +11.2% | 0.14% | -44.4% |
| Q1 2022 | $531,000 | -40.7% | 21,868 | -21.3% | 0.25% | -23.3% |
| Q4 2021 | $895,000 | – | 27,791 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |